Pasithea Therapeutics Corp. (KTTA) gained 38.68%, rising $0.41 to $1.47, after the company announced it priced a $60 million public offering, issuing 80 million shares (or equivalent pre-funded warrants) at $0.75 per share.
The company said the net proceeds will support ongoing development of its lead drug candidate PAS-004, fund clinical trials and other corporate activities, and extend its cash runway through at least the first half of 2028.
On the day of the announcement, KTTA saw unusually heavy trading volume as investors reacted to the financing deal and renewed confidence in its pipeline. The stock's 52-week range is approximately $0.45 - $2.40.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.